Immuron Ltd (IMRN)
NASDAQ:IMRN
Want to see IMRN full AI Analyst Report?
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$6.78M
Enterprise Value-$2.52M
Total Cash (Recent Filing)$9.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap-0.37
Enterprise Value/Revenue-0.28
Enterprise Value/Gross Profit-0.44
Enterprise Value/Ebitda0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$6.66M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt levels provide durable financial flexibility and lower solvency risk, allowing Immuron to fund operations or R&D through equity or non‑debt sources. This conservative capital structure supports resilience during prolonged development cycles and commercialization ramp.
High Gross MarginsSustained ~65% gross margins indicate strong unit economics for its colostrum‑derived products. Durable margin strength can support scalable profitability once sales grow, funding marketing and clinical investment without eroding product economics.
Non-dilutive R&D Cash InjectionA$1.12m non‑dilutive refund materially improves near‑term cash runway and funds sales/marketing plus R&D. This type of reimbursement reduces immediate financing needs, supports the profitability initiative and preserves capital structure while advancing commercialization.
Bears Say
Declining RevenueAn 11% revenue decline undermines scale economics and makes fixed costs harder to absorb. Persistent top‑line contraction pressures margins and elongates the path to sustainable profitability, heightening reliance on a narrow commercial product base and external funding.
Negative Cash Flow TrendNegative operating and free cash flow with a steep FCF decline reduce internal funding for growth and trials. Over months this forces recurring capital raises or cuts to commercial investment, increasing dilution risk and constraining the company’s ability to execute long‑term commercialization plans.
Deep Negative Profitability And ROESustained negative net and operating margins and negative ROE signal structural profitability problems. These losses erode shareholder equity and limit reinvestment capacity, meaning the company must achieve meaningful revenue growth or secure ongoing external funding to reach break‑even.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $6.78M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 114 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.192.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,166,340 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went up 17.103%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---